April 30, 2015
A class of ViroPharma Inc. shareholders claiming the company intentionally misled investors regarding market exclusivity for its signature gastrointestinal antibiotic asked a Pennsylvania federal judge Wednesday to approve an $8 million settlement reached through mediation, saying continued litigation could reduce or eliminate future recovery.
May 16, 2014
A Pennsylvania federal court on Friday refused to toss a class action against ViroPharma Inc., saying investors had enough evidence to support a claim that the company intentionally misled the public to believe it secured three years of market exclusivity for its signature gastrointestinal antibiotic.
May 18, 2012
A shareholder on Wednesday filed a proposed class action against ViroPharma Inc. seeking damages for stock losses allegedly sustained after the company wrongly led investors to believe it had secured three years of market exclusivity for its signature gastrointestinal antibiotic.